About Enteric Diseases
Enteric diseases are infections caused by ingested bacteria and viruses. Direct contact with contaminated feces or vomit is the secondary mode of contracting enteric ailments. Symptoms of enteric diseases include stomach pain, vomiting, diarrhea, nausea, weight loss, anorexia, and fever. Enteric diseases may lead to stunted growth, malnutrition, and impaired cognitive development. Enteric disease testing is performed on individuals using rapid tests, culture tests, enzyme immunoassay tests, and immunoassay tests.
Technavio’s analysts forecast the global enteric disease testing market to grow at a CAGR of 8.9% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global enteric disease testing market for 2016-2020. To calculate the market size, Technavio uses revenue generated from the sales of enteric disease testing products for Bacterial enterics (Clostridium difficile, Campylobacter, enterohemorrhagic Escherichia coli [EHEC], and Helicobacter pylori) and Viral enterics (Norovirus and Rotavirus) The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Enteric Disease Testing Market 2016-2020
Technavio recognizes the following companies as the key players in the global enteric disease testing market: Alere, bioMérieux, Cepheid, and DiaSorin.
Other Prominent Vendors in the market are BD, Biomerica, Coris BioConcept, Meridian Bioscience, Mobidiag, Quest Diagnostics, R-Biopharm, Trinity Biotech, and Thermo Fisher Scientific.
Commenting on the report, an analyst from Technavio’s team said that the development of novel NAAT for enteric disease testing is an important trend that will lead to the growth of this market. Currently, PCR represents the gold standard for nucleic acid-based diagnostics. However, the need for variations in temperature increases power consumption and costs for laboratories. Currently, life sciences companies and academics have developed an isothermal amplification-based diagnostic method to circumvent the need for thermocyclers. Isothermal-based methods incorporate all the temperature-dependent steps of PCR by incorporating enzymes. For example, HDA, an isothermal technique of nucleic acid amplification utilizes helicase for complementing the denaturation step at a high temperature, and the entire amplification is completed under isothermal conditions in the range of 140°F-149°F. The method has been used for rapid diagnostics of the E. coli pathogen. This method reduces the cost of instrumentation due to the usage of helicase to separate DNA, which eliminates the need for a thermocycler.
According to the report, high incidence of enteric diseases is one of the key drivers to augment the growth prospects for this market. Enteric diseases are the most common cause of mortality worldwide, after cardiovascular and respiratory diseases. There has been a rise in the incidence of enteric diseases globally over the past decade. For example, each year two billion cases of diarrhea are reported worldwide, and 760,000 children aged five of below succumb to the disease in Sub-Saharan Africa region. The high incidence of enteric diseases increases the demand for screening and testing of infected victims. This, in turn, drives the adoption of diagnostic tests, thereby contributing to market growth.
Further, the report states that stringent regulatory environment are hampering the growth of the market. The regulatory requirements for in vitro diagnostic (IVD) devices worldwide are specific and call for the provision of in-depth technical information, as most of them are classified as class III medical devices. The waiting period for regulatory approvals in the US is long, which can add to developmental expenses and delay return on investment for companies that are involved in the development of the test. In Europe, the 98/79/EC of October 27 Directive is enforced on all in vitro medical diagnostic devices. Canada issues a license to medical products based on the risk category it falls under. This license is issued by the Health Canada authorities and the time taken to issue this license depends on the category of the product. These licenses are subject to annual renewal. Multinational players have to comply with various stringent regulatory conditions of each country in which they operate, which affects their turnaround time, capital expenditure, and profitability.
Alere, bioMérieux, Cepheid, DiaSorin, BD, Biomerica, Coris BioConcept, Meridian Bioscience, Mobidiag, Quest Diagnostics, R-Biopharm, Trinity Biotech, Thermo Fisher Scientific.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook